ATE283365T1 - Il-1 rezeptor fusionsproteine verwendet als antagoniste und verfahren zu deren verwendung und herstellung - Google Patents

Il-1 rezeptor fusionsproteine verwendet als antagoniste und verfahren zu deren verwendung und herstellung

Info

Publication number
ATE283365T1
ATE283365T1 AT02007831T AT02007831T ATE283365T1 AT E283365 T1 ATE283365 T1 AT E283365T1 AT 02007831 T AT02007831 T AT 02007831T AT 02007831 T AT02007831 T AT 02007831T AT E283365 T1 ATE283365 T1 AT E283365T1
Authority
AT
Austria
Prior art keywords
antagonists
production
fusion proteins
proteins used
receptor fusion
Prior art date
Application number
AT02007831T
Other languages
English (en)
Inventor
George D Yancopoulos
Neil Stahl
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of ATE283365T1 publication Critical patent/ATE283365T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02007831T 1998-09-25 1999-09-22 Il-1 rezeptor fusionsproteine verwendet als antagoniste und verfahren zu deren verwendung und herstellung ATE283365T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10185898P 1998-09-25 1998-09-25
US09/313,942 US6472179B2 (en) 1998-09-25 1999-05-19 Receptor based antagonists and methods of making and using

Publications (1)

Publication Number Publication Date
ATE283365T1 true ATE283365T1 (de) 2004-12-15

Family

ID=26798712

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99952942T ATE336583T1 (de) 1998-09-25 1999-09-22 Antagonisten auf rezeptorgrundlage und verfahren zur deren herstellung und verwendung
AT02007831T ATE283365T1 (de) 1998-09-25 1999-09-22 Il-1 rezeptor fusionsproteine verwendet als antagoniste und verfahren zu deren verwendung und herstellung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT99952942T ATE336583T1 (de) 1998-09-25 1999-09-22 Antagonisten auf rezeptorgrundlage und verfahren zur deren herstellung und verwendung

Country Status (19)

Country Link
US (2) US6472179B2 (de)
EP (3) EP1229047B1 (de)
JP (1) JP3902728B2 (de)
CN (1) CN100345970C (de)
AT (2) ATE336583T1 (de)
AU (1) AU758970C (de)
BE (1) BE2010C021I2 (de)
CA (1) CA2345109C (de)
DE (3) DE69922269T2 (de)
DK (1) DK1229047T3 (de)
ES (2) ES2233733T3 (de)
FR (1) FR10C0025I2 (de)
HK (1) HK1045847B (de)
IL (2) IL142103A0 (de)
NO (2) NO329976B1 (de)
NZ (1) NZ510720A (de)
PL (1) PL201246B1 (de)
PT (1) PT1229047E (de)
WO (1) WO2000018932A2 (de)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
ES2226335T3 (es) 1998-01-23 2005-03-16 Immunex Corporation Receooctires de uk.18.
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
US7083949B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6927044B2 (en) * 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US20040120891A1 (en) * 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
DE16192152T1 (de) 2000-05-26 2020-08-06 Immunex Corporation Verwendung von interleukin-4 rezeptor (il-4r) antikörpern und zusammensetzungen davon
EP1290170A2 (de) 2000-06-16 2003-03-12 Asterion Limited Bindungsreagenzien: chimäre ligand/rezeptorproteine
EP2177616B1 (de) 2000-08-08 2012-02-29 ZymoGenetics, Inc. Lösliche Zcyctor 11 Cytokinrezeptoren
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20050112616A1 (en) * 2001-12-10 2005-05-26 William Lee Functionalized materials and libraries thereof
US7795213B2 (en) * 2001-12-13 2010-09-14 Posco Methods of contacting β amyloid protein with VEGF
US6846520B2 (en) * 2002-01-17 2005-01-25 Canon Kabushiki Kaisha Epoxy resin composition, surface treatment method, liquid-jet recording head and liquid-jet recording apparatus
WO2003092610A2 (en) * 2002-05-01 2003-11-13 Regeneron Pharmaceuticals, Inc. Methods of using cytokine antagonists to treat hiv infection and aids
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
NZ540555A (en) 2002-11-15 2008-04-30 Genmab As Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders
US6919012B1 (en) 2003-03-25 2005-07-19 Olimex Group, Inc. Method of making a composite article comprising a ceramic coating
AU2004224123A1 (en) 2003-03-26 2004-10-07 Apogenix Gmbh Treatment of viral infections
US20040224893A1 (en) * 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
WO2004098596A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising roflumilast and il-1 trap
AU2004262637A1 (en) * 2003-06-11 2005-02-17 Wyeth Method for producing a polypeptide
PT3095793T (pt) * 2003-07-28 2020-05-04 Genentech Inc Redução da lixiviação de proteína a durante a cromatografia por afinidade com proteína a
CA2536936A1 (en) * 2003-09-05 2005-03-17 National Research Council Of Canada E- and k-coiled-coil fusion proteins comprising tgf-b cell receptor domains
GEP20104991B (en) 2003-11-07 2010-05-25 Immunex Corp Antibodies that bind interleukin-4 receptor
CA2554596A1 (en) * 2004-02-27 2005-09-15 Regeneron Pharmaceuticals, Inc. Il-4/il-13 specific polypetides and therapeutic uses thereof
MXPA06014126A (es) 2004-06-04 2007-07-18 Regeneron Pharma Metodos para utilizar antagonistas il-1 para tratar enfermedades auto-inflamatorias.
ES2561048T3 (es) 2004-07-23 2016-02-24 Acceleron Pharma Inc. Polipéptidos del receptor ActRII
WO2006023665A2 (en) * 2004-08-17 2006-03-02 Regeneron Pharmaceuticals, Inc. Il-1 antagonist formulations
EP1630232B1 (de) * 2004-08-27 2008-07-02 CONARIS research institute AG Optimierte Nukleotidsequenzen die für sgp130 kodieren
US7786261B2 (en) * 2004-09-02 2010-08-31 National Research Council Of Canada Coiled-coil fusion proteins comprising cell receptor domains
ATE470454T1 (de) * 2004-09-13 2010-06-15 Genzyme Corp Multimere konstrukte
MX2007004374A (es) * 2004-10-12 2008-01-29 Amprotein Corp Proteina quimerica.
BRPI0516975A (pt) 2004-10-22 2008-09-30 Zymogenetics Inc anticorpo ou seu fragmento de ligação a antìgeno, composição farmacêutica, imunoconjugado, hibridoma, anticorpo monoclonal, e, uso de um anticorpo ou seu fragmento de ligação a antìgeno
US20090142294A1 (en) * 2005-01-25 2009-06-04 Apollo Life Sciences Limited Parameter selected gm-csf, il-3, il-4, il-5 and chimeras thereof for therapeutic and diagnostic purposes
EP2586459B1 (de) 2005-03-25 2017-05-24 Regeneron Pharmaceuticals, Inc. VEGF-Antagonistenformulierungen
US7732167B2 (en) * 2005-06-17 2010-06-08 Regeneron Pharmaceuticals, Inc. Interferon-α/β binding fusion proteins and therapeutic uses thereof
US7608430B2 (en) * 2005-07-08 2009-10-27 Regeneron Pharmaceuticals, Inc. Interferon-γ antagonists and therapeutic uses thereof
ES2460517T3 (es) 2005-07-25 2014-05-13 Emergent Product Development Seattle, Llc Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20
US7666622B2 (en) * 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
WO2007061981A2 (en) 2005-11-21 2007-05-31 Lumera Corporation Surface plasmon resonance spectrometer with an actuator-driven angle scanning mechanism
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
CN112457389A (zh) * 2005-11-23 2021-03-09 阿塞勒隆制药公司 Activin-ActRIIa拮抗剂及其促进骨骼生长的应用
ME00380B (me) 2005-11-23 2011-10-10 Acceleron Pharma Inc Amtagonisti aktivin-actriia i primjene za stimulaciju rasta kosti
US7463358B2 (en) 2005-12-06 2008-12-09 Lumera Corporation Highly stable surface plasmon resonance plates, microarrays, and methods
ES2395969T3 (es) 2006-03-24 2013-02-18 Merck Patent Gmbh Dominios de proteínas heterodiméricas genéticamente modificados
EP2418223A3 (de) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Einkettige, multivalente Bindungsproteine mit Effektorfunktion
EP3753548A1 (de) 2006-06-16 2020-12-23 Regeneron Pharmaceuticals, Inc. Vegf-antagonisten-formulierungen zur intravitrealen verabreichung
ATE480568T1 (de) 2006-06-30 2010-09-15 Conaris Res Inst Ag Verbesserte sgp 130fc dimere
AU2007279205B2 (en) * 2006-07-28 2013-09-26 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
US8106004B2 (en) * 2006-07-28 2012-01-31 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
US7632490B2 (en) * 2006-10-20 2009-12-15 Regeneron Pharmaceuticals, Inc. Use of IL-1 antagonists to treat gout
AU2007309470B2 (en) * 2006-10-20 2013-05-23 Regeneron Pharmaceuticals, Inc. Use of IL-1 antagonists to treat gout and pseudogout
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
WO2008093756A1 (ja) * 2007-01-30 2008-08-07 Niigata University 生物学的製剤
US9526759B2 (en) 2007-02-01 2016-12-27 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
KR101672156B1 (ko) 2007-02-09 2016-11-02 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
US8318135B2 (en) 2007-03-19 2012-11-27 National Research Council Of Canada Antagonist of ligands and uses thereof
WO2009010539A2 (de) * 2007-07-19 2009-01-22 Ablynx. N.V. Receptor for interleukin-6 (il-6) form macaca fascicularis
CN107412734A (zh) 2007-09-18 2017-12-01 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
US20110008332A1 (en) * 2007-10-31 2011-01-13 The Scripps Research Institute Combination Therapy to Treat Persistent Viral Infections
US8004669B1 (en) 2007-12-18 2011-08-23 Plexera Llc SPR apparatus with a high performance fluid delivery system
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
LT3750552T (lt) 2008-08-14 2023-06-26 Acceleron Pharma Inc. Gdf gaudyklės
CA2737271C (en) * 2008-09-17 2020-06-23 National Research Council Of Canada Hetero-multivalent binding agents for members of the tgf.beta. superfamily
KR20170105124A (ko) 2008-11-26 2017-09-18 암젠 인크 액티빈 ｉｉｂ 수용체 폴리펩타이드의 변이체 및 이의 용도
MX385318B (es) 2009-06-08 2025-03-18 Acceleron Pharma Inc Metodos para aumentar adipocitos termogenicos.
JP2012529294A (ja) 2009-06-12 2012-11-22 アクセルロン ファーマ， インコーポレイテッド 切断型ＡｃｔＲＩＩＢ−Ｆｃ融合タンパク質
EP2501400B1 (de) 2009-11-17 2017-11-01 Acceleron Pharma, Inc. Actriib-proteine und varianten davon sowie ihre anwendung zur utrophin-induktion für therapien gegen muskuläre dystrophie
WO2012064771A1 (en) 2010-11-08 2012-05-18 Acceleron Pharma, Inc. Actriia binding agents and uses thereof
CN103492416A (zh) 2011-04-15 2014-01-01 默克专利股份公司 用于癌症中使用的抗il-1r1抑制剂
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
CN104379159A (zh) 2011-12-19 2015-02-25 安姆根公司 变体激活素受体多肽,单独或与化疗结合,及其用途
RU2018145985A (ru) 2012-11-02 2019-02-18 Селджин Корпорейшн Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
CA2894219C (en) * 2012-12-10 2020-08-11 Vib Vzw Novel interleukin-33 inhibitors
AU2014212014A1 (en) 2013-02-01 2015-08-27 Amgen Inc. Administration of an anti-activin-A compound to a subject
JP6225197B2 (ja) 2013-02-15 2017-11-01 アール−ファーム・ジョイント・ストック・カンパニーＲ−Ｐｈａｒｍ，Ｊｓｃ ＩＬ−１β阻害剤組成物およびその使用
US12180264B2 (en) 2014-03-24 2024-12-31 R-Pharm Overseas, Inc. IL1-R1 derived inhibitor of IL-1β and use thereof
TN2016000553A1 (en) 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
MA40354A (fr) 2014-07-18 2017-05-24 Sanofi Sa Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MD3227325T2 (ro) * 2014-12-01 2024-09-30 Ferring Bv Compoziții de inhibitor selectiv trans-semnalizare de IL-6
MX2017007067A (es) 2014-12-01 2018-04-30 Ferring Bv Administracion de un inhibidor selectivo de la trans-señalizacion de il-6.
DK3227675T3 (da) 2014-12-03 2023-05-30 Celgene Corp Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom
GB201503453D0 (en) 2015-03-01 2015-04-15 Jain Arjun Endothelin-1"sponge"
JP7240812B2 (ja) * 2015-05-12 2023-03-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 多量体タンパク質の純度の決定
MX2018003292A (es) 2015-09-21 2018-08-01 Aptevo Res & Development Llc Polipéptidos de unión a cd3.
JP7421338B2 (ja) 2016-09-27 2024-01-24 エピセントアールエックス，インコーポレイテッド 免疫調節融合タンパク質
BR112019021812A2 (pt) 2017-04-21 2020-05-26 Kindred Biosciences, Inc. Molécula receptora de il4/il13 para uso veterinário
AU2018338612A1 (en) 2017-09-27 2020-05-07 Epicentrx, Inc. Immunomodulatory fusion proteins
BR112020017382A2 (pt) 2018-03-09 2021-01-26 Agenus Inc. anticorpos anti-cd73 e métodos de uso dos mesmos
WO2020018700A1 (en) 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
CN110950965B (zh) * 2018-09-26 2021-10-15 重庆精准生物技术有限公司 抗人cd123的嵌合抗原受体及其应用
TWI904261B (zh) 2020-10-19 2025-11-11 美商碩騰服務公司 犬及貓抑瘤素Ｍ受體β之抗體及其用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
AU651596B2 (en) * 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
DK0835939T3 (da) * 1990-06-28 2006-03-13 Sanofi Aventis Deutschland Fusionsproteiner med andele af immunglobulin, deres fremstilling og anvendelse
EP0533006A1 (de) * 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimäre Interleukin 5-Rezeptor/Immunoglobulin-Polypeptide
WO1993007863A1 (en) * 1991-10-15 1993-04-29 Mullarkey Michael F Methods and compositions for treating allergic reactions
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
WO1993018047A1 (en) * 1992-03-09 1993-09-16 Ludwig Institute For Cancer Research Nucleic acid sequences coding for or complementary to nucleic acid sequences coding for interleukin 9 receptor
WO1993019163A1 (en) * 1992-03-18 1993-09-30 Yeda Research And Development Co, Ltd. Chimeric receptor genes and cells transformed therewith
US8211422B2 (en) * 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
AU671116B2 (en) * 1992-03-30 1996-08-15 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
JP3255699B2 (ja) 1992-04-23 2002-02-12 味の素株式会社 ヒトＩＬ−２レセプターγ鎖分子
EP0693084A4 (de) * 1993-04-06 1999-06-02 Hutchinson Fred Cancer Res Chimäre cytokinrezeptoren in lymphozyten
EP0716703A1 (de) * 1993-09-03 1996-06-19 PRENDERGAST, Kenneth, Francis Glycophorin bindende proteine (gbp130) fusionszusammensetzungen
JPH09503673A (ja) * 1993-10-14 1997-04-15 プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ ニューロン細胞の誘導および維持法
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
IL114825A0 (en) * 1994-08-04 1995-12-08 Regeneron Pharma Rtk/cytokine receptor chimeras
WO1996011213A1 (en) 1994-10-07 1996-04-18 Amgen Boulder Inc. Dimeric il-4 inhibitors
US5741899A (en) * 1995-02-02 1998-04-21 Cell Genesys, Inc. Chimeric receptors comprising janus kinase for regulating cellular pro liferation
US5837816A (en) * 1995-05-10 1998-11-17 Chiron Corporation Interleukin-2 receptor subunit ectodomain fusion protein comprising a leucine zipper domain
GB9526131D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US5776731A (en) * 1996-02-21 1998-07-07 Immunex Corporation DNA encoding type-I interleukin-I receptor-like protein designated 2F1
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
WO1998002558A2 (en) * 1996-07-17 1998-01-22 University Of Medicine And Dentistry Of New Jersey Chimeric receptors for jak-stat signal transduction
WO1998008969A1 (en) * 1996-08-26 1998-03-05 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
GB9625899D0 (en) 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
ES2226335T3 (es) * 1998-01-23 2005-03-16 Immunex Corporation Receooctires de uk.18.

Also Published As

Publication number Publication date
IL142103A0 (en) 2002-03-10
HK1045847A1 (en) 2002-12-13
AU6499499A (en) 2000-04-17
NO2011003I1 (no) 2011-05-02
BE2010C021I2 (de) 2018-12-04
DE122010000023I1 (de) 2012-04-26
NO2011003I2 (de) 2011-04-11
DK1229047T3 (da) 2005-02-21
ES2233733T3 (es) 2005-06-16
NO20011513D0 (no) 2001-03-23
PL348529A1 (en) 2002-06-03
AU758970C (en) 2007-05-03
DE69922269D1 (de) 2004-12-30
DE69932832T2 (de) 2007-02-08
EP1405915A1 (de) 2004-04-07
US20020164690A1 (en) 2002-11-07
PT1229047E (pt) 2005-03-31
HK1035377A1 (en) 2001-11-23
ES2267300T3 (es) 2007-03-01
JP2002525119A (ja) 2002-08-13
WO2000018932A9 (en) 2000-08-31
WO2000018932A2 (en) 2000-04-06
EP1229047B1 (de) 2004-11-24
AU758970B2 (en) 2003-04-03
FR10C0025I2 (fr) 2011-04-01
CN100345970C (zh) 2007-10-31
CN1357049A (zh) 2002-07-03
EP1115876B1 (de) 2006-08-16
PL201246B1 (pl) 2009-03-31
NZ510720A (en) 2003-11-28
WO2000018932A3 (en) 2000-11-02
NO20011513L (no) 2001-05-25
EP1115876A2 (de) 2001-07-18
JP3902728B2 (ja) 2007-04-11
HK1045847B (en) 2005-03-24
US6472179B2 (en) 2002-10-29
NO329976B1 (no) 2011-01-31
FR10C0025I1 (de) 2010-05-21
DE122010000023I2 (de) 2012-04-26
DE69932832D1 (de) 2006-09-28
EP1229047A3 (de) 2002-10-02
DE69922269T2 (de) 2005-12-01
CA2345109C (en) 2012-12-18
ATE336583T1 (de) 2006-09-15
US20020012962A1 (en) 2002-01-31
CA2345109A1 (en) 2000-04-06
IL142103A (en) 2007-07-04
EP1229047A2 (de) 2002-08-07

Similar Documents

Publication Publication Date Title
ATE283365T1 (de) Il-1 rezeptor fusionsproteine verwendet als antagoniste und verfahren zu deren verwendung und herstellung
EP1572967A4 (de) Auf il-1-rezeptor beruhende antagonisten sowie herstellungs- und verwendungsverfahren
ATE490323T1 (de) Adiponektin-rezeptor und dafür kodierendes gen
ATE448246T1 (de) Sekretierte und transmembran-polypeptide sowie nukleinsäuren zu deren kodierung
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
NO961115D0 (no) Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser
ATE541931T1 (de) Il-17-homologe polypeptide und ihre therapeutische verwendung
ATE536372T1 (de) Verfahren zur hoher expression der aktiven form von lymphotoxin-beta-rezeptor-immunglobulin fusionsproteinen, und deren reinigung
DE60236921D1 (de) Verfahren und zusammensetzungen zur verwendung von mhc-klasse ii-invariante-kette-polypeptid als rezeptor für makrophagenwanderung-hemmfaktor
DK1321477T3 (da) Fremgangsmåde til frembringelsen af genetisk modificerede vertebrate precursor-lymfocytter og anvendelse deraf til fremstillingen af heterologe bindende proteiner
ATE345382T1 (de) 2,6-beta-d-fruktanhydrolase enzym und verfahren zu dessen verwendung
DE69507017D1 (de) Cai-resistenzproteine kodierende dna, und ihre verwendung
ATE332974T1 (de) Il-1/tnf-alpha-activated kinase (itak), und verfahren zu ihrer herstellung und verwendung
ATE374819T1 (de) Antagonistischer antikörper gegen pro842
DE602004030899D1 (de) Neues screening-verfahren
DE60308176D1 (de) Vorrichtung von peptid- oder proteindarstellung, verfahren zu deren herstellung und deren verwendung
WO2000006733A3 (en) T cell receptor proteins, nucleic acid molecules, and uses thereof
DE69935973D1 (de) Zusammensetzungen mit fusionsproteinen der kinase wee1, nukleotidsequenzen, expressionsysteme und verfahren zu deren verwendung